These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 9236420

  • 1. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions.
    Simpfendorfer C, Kottke-Marchant K, Lowrie M, Anders RJ, Burns DM, Miller DP, Cove CS, DeFranco AC, Ellis SG, Moliterno DJ, Raymond RE, Sutton JM, Topol EJ.
    Circulation; 1997 Jul 01; 96(1):76-81. PubMed ID: 9236420
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
    Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ.
    Circulation; 1998 Sep 29; 98(13):1268-78. PubMed ID: 9751674
    [Abstract] [Full Text] [Related]

  • 3. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1997 Aug 19; 96(4):1117-21. PubMed ID: 9286938
    [Abstract] [Full Text] [Related]

  • 4. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
    Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1996 Sep 01; 94(5):906-10. PubMed ID: 8790024
    [Abstract] [Full Text] [Related]

  • 5. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ, Cox D, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2000 Nov 01; 295(2):670-6. PubMed ID: 11046104
    [Abstract] [Full Text] [Related]

  • 6. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.
    O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R.
    N Engl J Med; 2000 May 04; 342(18):1316-24. PubMed ID: 10793164
    [Abstract] [Full Text] [Related]

  • 7. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
    Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins MA, Kleiman NS, Théroux P, White HD, Topol EJ.
    Eur Heart J; 2002 Sep 04; 23(18):1441-8. PubMed ID: 12208224
    [Abstract] [Full Text] [Related]

  • 8. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD, ACUITY Investigators.
    JAMA; 2007 Feb 14; 297(6):591-602. PubMed ID: 17299194
    [Abstract] [Full Text] [Related]

  • 9. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD.
    Haemostasis; 2000 Feb 14; 30 Suppl 3():27-43. PubMed ID: 11182626
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
    Akkerhuis KM, van Den Brand MJ, van Der Zwaan C, Peels HO, Suryapranata H, van Der Wieken LR, Stibbe J, Hoffmann J, Baardman T, Deckers JW, Simoons ML.
    Heart; 2001 Apr 14; 85(4):444-50. PubMed ID: 11250974
    [Abstract] [Full Text] [Related]

  • 11. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
    Bosch X, Marrugat J.
    Cochrane Database Syst Rev; 2001 Apr 14; (4):CD002130. PubMed ID: 11687143
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
    Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF.
    Circulation; 1994 Feb 14; 89(2):596-603. PubMed ID: 7508826
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E.
    Circulation; 1998 Feb 03; 97(4):340-9. PubMed ID: 9468207
    [Abstract] [Full Text] [Related]

  • 14. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
    Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G.
    Circulation; 1996 Nov 01; 94(9):2083-9. PubMed ID: 8901655
    [Abstract] [Full Text] [Related]

  • 15. Xemilofiban/orbofiban: insight into drug development.
    Anders R, Kleiman J, Nicholson N, Wazowicz B, Burns D.
    Cardiovasc Drug Rev; 2001 Nov 01; 19(2):116-32. PubMed ID: 11484066
    [Abstract] [Full Text] [Related]

  • 16. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
    Byrne A, Moran N, Maher M, Walsh N, Crean P, Fitzgerald DJ.
    Arterioscler Thromb Vasc Biol; 1997 Nov 01; 17(11):3224-9. PubMed ID: 9409315
    [Abstract] [Full Text] [Related]

  • 17. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J, Berent R, Lassnig E, Weber T, Maurer E, Eber B.
    Herz; 2003 Aug 01; 28(5):393-403. PubMed ID: 12928738
    [Abstract] [Full Text] [Related]

  • 18. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 19. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL.
    Am J Cardiovasc Drugs; 2003 Sep 17; 3(2):101-12. PubMed ID: 14727937
    [Abstract] [Full Text] [Related]

  • 20. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ.
    Am J Cardiol; 1997 Oct 15; 80(8):985-8. PubMed ID: 9352964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.